ÿþ<html> <head> <title>CEF Peptide Pools for activating CD8 memory cells</title> <LINK type="text/css" rel="stylesheet" href="../style.css"> <meta content="CEF peptide pools for ELISPOT assays" name="description"> <meta content="CEF peptide pools, elispot" name="keywords"></head> <body> <table id="Table1" cellSpacing="0" cellPadding="0" width="1010" align="left" border="0"> <tr> <td width="50"></td> <td width="20"></td> <td width="300"></td> <td width="20"></td> <td width="300"></td> <td width="20"></td> <td width="278"></td> <td width="22"></td> <td width="40"></td> </tr> <tr> <td width="50"></td> <td vAlign="bottom" width="1000" colSpan="8"><IMG title="ELISPOT, peptides" src="../images/header-immunospot-flyer.gif"></td> </tr> <tr> <td width="50" height="20"></td> <td width="20" height="20"></td> <td vAlign="bottom" width="918" colSpan="5" height="10"><A class="headlink" href="products-cef-peptides.html"><IMG height="15" src="../images/arrow_bwd.gif" width="15" border="0"> CEF Peptide Pools&ndash;The Positive Control for Activating CD8 Memory Cells</A></td> <td width="22"><img src="../images/flyer-short-vert-line.gif"></td> <td width="40"></td> </tr> <tr> <td width="50" height="10"></td> <td vAlign="bottom" width="960" colSpan="7" height="10"><IMG src="../images/flyer-top-line.gif"></td> <td width="40" height="10"></td> </tr> <tr> <td width="50" rowSpan="2"></td> <td vAlign="top" align="left" width="20" rowSpan="2"><IMG src="../images/peptides-flyer-left-line.gif"></td> <td vAlign="top" align="left" width="300" colSpan="1" rowSpan="2"> <p><span class="darkred_emphasis">CTL, in collaboration with PANATecs, offers two peptide pools that cover HLA class I restricted T cell epitopes of Cytomegalovirus, Epstein-Barr Virus, and Flu Virus (CEF peptides).</span> <p> Most humans have been infected and have developed CD8 positive cell responses to these viruses; in addition, the determinants have been selected to cover common HLA-alleles. For these reasons, these peptides will stimulate the CD8 memory cells of most human subjects. CEF peptides are therefore an ideal positive control when testing PBMC in ELISPOT assays, intracellular cytokine staining, cytokine bead arrays, ELISA or any other test system that aims for detecting antigen-specific T cell recall responses. <p>Traditionally phytohemagglutinin (PHA), PMA-ionomycin, or anti-CD3 antibody have been used as a positive control for ELISPOT assays. However, such stimuli are polyclonal and hence too strong to reflect on antigen-specific T cell responses. PHA and PMAionomycin activate many cell types in addition to T cells. The <i>per cell</i> cytokine production induced by the former is significantly more than antigen-triggered cytokine production by T cells. The CEF peptide pools circumvent these problems. <p>CEF peptides stimulate only CD8+ cells. In addition to using CEF peptides as a positive control for CD8 cell functionality, they can also be used to control for the adequacy of CD8 T cell depletion. <H3>23 CEF Class I Peptide Pool</H3> <p>The classic 23 HLA class I-restricted CEF T cell epitopes. The pool covers determinants restricted by 11 HLA alleles: A1, A2, A3, A11, A24, A68, B7, B8, B27, B35, and B44. Most Caucasian individual express at least one of these alleles and the 23 peptides selected cover CD8 cell epitopes in most Caucasians. [1]</p> </td> <td rowSpan="2"></td> <td colSpan="4" valign="top" height="175"><IMG title="peptides, positive controls" src="../images/peptides.jpg"></td> </tr> <tr> <td vAlign="top" width="300"> <H3>32 CEF Class I Peptide Pool</H3> <P> The extended peptide pool consisting of 32 HLA class I restricted CEF T cell epitopes, and covering 15 HLA class I alleles, in particular HLA: A1, A2, A0201, A3, A11, A24, A68, A6081, B7, B8, B18, B27, B35,B44, B0702. Because the classic 23 CEF peptides failed to elicit CD8 cell recall responses in all Caucasians, the original peptide pool by Currier, et al. was extended by nine peptides that cover determinants and more HLA alleles. The extended 32 peptide pool elicits recall responses in most humans. <P>LIT: [1] <EM>A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays: J.R. Currier, et al.; J.Immunol. Methods 260, 157 (2002)</EM></P> </td> <td></td> <td vAlign="top" width="300" colspan="2"> <H3>Cryopreserved PBMC</H3> <P>CTL also offers cryopreserved PBMCs that have pre-defined reactivity for the CEF peptide pools and for the individual peptides of the pool as well as HLA class I and II high resolution haplotype characterization. These cryopreserved PBMCs are useful for assay development, standardization, and as basic laboratory research reagents.</P> <img title="The ELISPOT experts" src="../images/ctl-logo-with-address.gif"> </td> <td width="40"></td> </tr> <tr> <td width="50"></td> <td vAlign="top" width="960" colSpan="7" height="10"><IMG src="../images/flyer-bottom-line.gif"></td> <td width="40"></td> </tr> <tr> <td colSpan="7"><NOSCRIPT><BR> <A title="ELISPOT" href="index.html" target="_top">Back to the CTL home page and more ELISPOT info</A> </NOSCRIPT></td> </tr> </table> </body> </html>